| 4676- | CUR, | Curcumin suppresses stem-like traits of lung cancer cells via inhibiting the JAK2/STAT3 signaling pathway |
| - | vitro+vivo, | Lung, | H460 |
| 4710- | CUR, | Curcumin inhibits migration and invasion of non-small cell lung cancer cells through up-regulation of miR-206 and suppression of PI3K/AKT/mTOR signaling pathway |
| - | in-vitro, | Lung, | A549 |
| 4707- | CUR, | The Potential Role of Curcumin as a Regulator of microRNA in Colorectal Cancer: A Systematic Review |
| - | Review, | Var, | NA |
| 4708- | CUR, | Molecular mechanisms underlying curcumin-mediated microRNA regulation in carcinogenesis; Focused on gastrointestinal cancers |
| - | Review, | GC, | NA |
| 2312- | CUR, | Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy |
| - | Review, | Var, | NA |
| 2304- | CUR, | Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HEK293 |
| 2305- | CUR, | Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN |
| - | in-vitro, | BC, | MCF7 |
| 2307- | CUR, | Cell-Type Specific Metabolic Response of Cancer Cells to Curcumin |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | Laryn, | FaDu |
| 2308- | CUR, | Counteracting Action of Curcumin on High Glucose-Induced Chemoresistance in Hepatic Carcinoma Cells |
| - | in-vitro, | Liver, | HepG2 |
| 2466- | CUR, | Regulatory Effects of Curcumin on Platelets: An Update and Future Directions |
| - | Review, | Nor, | NA |
| 2579- | CUR, | ART/DHA, | Curcumin-Artemisinin Combination Therapy for Malaria |
| - | in-vivo, | NA, | NA |
| 2654- | CUR, | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| - | Review, | Var, | NA |
| 2688- | CUR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2819- | CUR, | Chemo, | Curcumin as a hepatoprotective agent against chemotherapy-induced liver injury |
| - | Review, | Var, | NA |
| 2820- | CUR, | Hepatoprotective Effect of Curcumin on Hepatocellular Carcinoma Through Autophagic and Apoptic Pathways |
| - | in-vitro, | HCC, | HepG2 |
| 2821- | CUR, | Antioxidant curcumin induces oxidative stress to kill tumor cells (Review) |
| - | Review, | Var, | NA |
| 2822- | CUR, | Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies |
| - | Analysis, | Nor, | NA |
| 2823- | CUR, | Binding of curcumin with glyoxalase I: Molecular docking, molecular dynamics simulations, and kinetics analysis |
| - | Study, | Nor, | NA |
| 2811- | CUR, | Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study |
| - | Human, | Pca, | NA |
| 2817- | CUR, | Neuroprotection by curcumin: A review on brain delivery strategies |
| - | Review, | Nor, | NA |
| 2812- | CUR, | Curcumin Induces High Levels of Topoisomerase I− and II−DNA Complexes in K562 Leukemia Cells |
| - | in-vitro, | AML, | K562 |
| 2810- | CUR, | Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials |
| - | Review, | Nor, | NA |
| 2809- | CUR, | Comparative absorption of curcumin formulations |
| - | in-vivo, | Nor, | NA |
| 2808- | CUR, | Iron chelation by curcumin suppresses both curcumin-induced autophagy and cell death together with iron overload neoplastic transformation |
| - | in-vitro, | Liver, | HUH7 |
| 2818- | CUR, | Novel Insight to Neuroprotective Potential of Curcumin: A Mechanistic Review of Possible Involvement of Mitochondrial Biogenesis and PI3/Akt/ GSK3 or PI3/Akt/CREB/BDNF Signaling Pathways |
| - | Review, | AD, | NA |
| 2813- | CUR, | Oxidative Metabolites of Curcumin Poison Human Type II Topoisomerases |
| - | Review, | NA, | NA |
| 2814- | CUR, | Curcumin in Cancer and Inflammation: An In-Depth Exploration of Molecular Interactions, Therapeutic Potentials, and the Role in Disease Management |
| - | Review, | Var, | NA |
| 2815- | CUR, | Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin |
| 2816- | CUR, | NEUROPROTECTIVE EFFECTS OF CURCUMIN |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2980- | CUR, | Inhibition of NF B and Pancreatic Cancer Cell and Tumor Growth by Curcumin Is Dependent on Specificity Protein Down-regulation |
| - | in-vivo, | PC, | NA |
| 2979- | CUR, | GB, | Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death |
| - | in-vitro, | Lung, | H157 | - | in-vitro, | Lung, | H1299 |
| 2978- | CUR, | N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells |
| - | in-vitro, | Lung, | A549 |
| 2977- | CUR, | Curcumin Down-Regulates Toll-Like Receptor-2 Gene Expression and Function in Human Cystic Fibrosis Bronchial Epithelial Cells |
| - | in-vitro, | CF, | NA |
| 2976- | CUR, | Curcumin suppresses the proliferation of oral squamous cell carcinoma through a specificity protein 1/nuclear factor‑κB‑dependent pathway |
| - | in-vitro, | Oral, | HSC3 | - | in-vitro, | HNSCC, | CAL33 |
| 2975- | CUR, | Curcumin inhibits proliferation, migration and neointimal formation of vascular smooth muscle via activating miR-22 |
| - | in-vivo, | Nor, | NA |
| 2974- | CUR, | Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT15 | - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | SW-620 | - | in-vivo, | NA, | NA |
| 6238- | CUSP9, | A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3 |
| - | Trial, | GBM, | NA |
| 6235- | CUSP9, | Exhaustive in vitro evaluation of the 9-drug cocktail CUSP9 for treatment of glioblastoma |
| - | in-vitro, | GBM, | NA |
| 6236- | CUSP9, | EP, | Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro |
| - | in-vitro, | GBM, | U251 |
| - | NA, | GBM, | NA |
| 6234- | CUSP9, | In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma |
| - | Human, | GBM, | NA |
| - | Review, | GBM, | NA |
| 6239- | CUSP9, | The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy |
| - | in-vitro, | GBM, | NA |
| 6240- | CUSP9, | A Pilot Clinical Study of CUSP9v3: Nine Repurposed Drugs Combined With Temozolomide for the Treatment of Recurrent Glioblastoma |
| - | Human, | GBM, | NA |
| 6241- | CUSP9, | RECURRENT GLIOBLASTOMA: INITIAL EXPERIENCES WITH COMPASSIONATE-USE CUSP9v3/v4 |
| - | Trial, | GBM, | NA |
| - | Analysis, | GBM, | NA |
| 6249- | Cyc, | Cyclopamine tartrate, an inhibitor of Hedgehog signaling, strongly interferes with mitochondrial function and suppresses aerobic respiration in lung cancer cells |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H1299 |
| 6242- | Cyc, | The teratogenic Veratrum alkaloid cyclopamine inhibits Sonic hedgehog signal transduction |
| - | in-vivo, | Nor, | NA |
| 6243- | Cyc, | Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened |
| - | Study, | Var, | NA |
| 6244- | Cyc, | Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours |
| - | in-vivo, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid